Thus, anti-CGRP mAbs could represent effective tools in the therapeutic arsenal against unresponsive migraine; however, deep monitoring of efficacy and safety (i.e., production of toxic metabolites, immunogenicity with ADA, neutralizing antibodies and tissue cross-reactivity and side effects) is mandatory (Taylor, 2018). Here, ADA is linked to migraine disorder.